Mechanism of Action
ZERBAXA® (ceftolozane and tazobactam) combines a novel cephalosporin that has bactericidal action with a proven beta-lactamase inhibitor
Learn about:
Mechanism of action

Antimicrobial activity
ZERBAXA has been shown to be active against the following bacteria, both in vitro and in clinical infections.
- Hospital-acquired Bacterial Pneumonia and
- Ventilator-associated Bacterial Pneumonia
- (HABP/VABP)
|
|||
---|---|---|---|
|
|
|
|
|
|
|
|
Complicated Urinary Tract Infections (cUTI)
|
|||
---|---|---|---|
|
|
|
|
- Complicated Intra-abdominal Infections (cIAI)
- combined with metronidazole
|
|||
---|---|---|---|
|
|
|
|
|
|
||
|
|||
|
|
||
|
|||
|
|||
|
Mechanisms of resistance
ZERBAXA demonstrated in vitro activity in the presence of certain mechanisms of resistance
ZERBAXA demonstrated in vitro activity against Enterobacteriaceae in the presence of some extended spectrum β-lactamases (ESBLs) and other beta-lactamases and against P. aeruginosa isolates with certain mechanisms of resistance
- The clinical significance of in vitro data is unknown